[go: up one dir, main page]

MXPA04003674A - Uso mejorado de compuesto antitumoral en terapia de cancer. - Google Patents

Uso mejorado de compuesto antitumoral en terapia de cancer.

Info

Publication number
MXPA04003674A
MXPA04003674A MXPA04003674A MXPA04003674A MXPA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A
Authority
MX
Mexico
Prior art keywords
cancer therapy
improved use
antitumoral compound
antitumoral
compound
Prior art date
Application number
MXPA04003674A
Other languages
English (en)
Inventor
Hidalgo Manuel
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MXPA04003674A publication Critical patent/MXPA04003674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se dan programas de dosificacion mejorados para ecteinascidin 743 para el tratamiento de cancer.
MXPA04003674A 2001-10-19 2002-10-21 Uso mejorado de compuesto antitumoral en terapia de cancer. MXPA04003674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34841401P 2001-10-19 2001-10-19
PCT/US2002/033548 WO2003039571A1 (en) 2001-10-19 2002-10-21 Improved use of antitumoral compound in cancer therapy

Publications (1)

Publication Number Publication Date
MXPA04003674A true MXPA04003674A (es) 2004-07-23

Family

ID=23367939

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003674A MXPA04003674A (es) 2001-10-19 2002-10-21 Uso mejorado de compuesto antitumoral en terapia de cancer.

Country Status (15)

Country Link
US (1) US20050004018A1 (es)
EP (1) EP1435988A4 (es)
JP (1) JP2005509650A (es)
KR (1) KR20050038578A (es)
CN (1) CN1606449A (es)
AU (1) AU2002343548B2 (es)
BR (1) BR0213424A (es)
CA (1) CA2462502A1 (es)
HU (1) HUP0401903A3 (es)
IL (1) IL161430A0 (es)
MX (1) MXPA04003674A (es)
NO (1) NO20042035L (es)
PL (1) PL368458A1 (es)
RU (1) RU2306933C2 (es)
WO (1) WO2003039571A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP4391083B2 (ja) * 2000-11-06 2009-12-24 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
DK1689404T3 (da) * 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
ATE430586T1 (de) * 2004-10-26 2009-05-15 Pharma Mar Sa Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments
DK2716301T3 (en) * 2007-02-16 2017-07-31 Merrimack Pharmaceuticals Inc ANTIBODIES AGAINST ERBB3 AND APPLICATIONS THEREOF
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EA022884B1 (ru) * 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
CA2792327C (en) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CA2841748C (en) 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
EP2919772B1 (en) 2012-11-13 2019-03-27 NuSirt Sciences, Inc. Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
CZ302498B6 (cs) * 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
JP5219323B2 (ja) * 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
JP4391083B2 (ja) * 2000-11-06 2009-12-24 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제

Also Published As

Publication number Publication date
EP1435988A4 (en) 2008-01-09
CA2462502A1 (en) 2003-05-15
HUP0401903A3 (en) 2008-07-28
KR20050038578A (ko) 2005-04-27
EP1435988A1 (en) 2004-07-14
HUP0401903A2 (hu) 2005-01-28
RU2306933C2 (ru) 2007-09-27
RU2004115110A (ru) 2005-03-10
WO2003039571A1 (en) 2003-05-15
AU2002343548B8 (en) 2003-05-19
AU2002343548B2 (en) 2007-11-08
US20050004018A1 (en) 2005-01-06
IL161430A0 (en) 2004-09-27
BR0213424A (pt) 2004-12-14
CN1606449A (zh) 2005-04-13
NO20042035L (no) 2004-05-18
JP2005509650A (ja) 2005-04-14
PL368458A1 (en) 2005-03-21

Similar Documents

Publication Publication Date Title
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MY136520A (en) Novel compounds
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
IL164599A0 (en) Combination therapy for the treatment of cancer
AP2000001785A0 (en) Medicaments
IL163573A0 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
SI1663242T1 (sl) 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
TW200508214A (en) Novel compounds
PL354540A1 (en) Drugs for the treatment of malignant tumours
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
DE69905170D1 (en) Thiazolopyrimidinderivate
IL164896A0 (en) Immunoconjugates for the treatment of tumours
IL146125A0 (en) Novel quinones as disease therapies
HUP0500424A3 (en) Combination therapy for the treatment of cancer
YU13301A (sh) Muskarinski agonisti i antagonisti
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
GB9907571D0 (en) Compounds
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
PT1303520E (pt) Compostos terapêuticos e métodos
MXPA04005942A (es) Composiciones y metodos de sintaxina 3.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal